These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 24914076)

  • 1. Comparison is beyond IPASS and OPTIMAL.
    Lam KC; Mok TS
    Hong Kong Med J; 2014 Jun; 20(3):176-7. PubMed ID: 24914076
    [No Abstract]   [Full Text] [Related]  

  • 2. Effectiveness and cost-effectiveness of erlotinib versus gefitinib in first-line treatment of epidermal growth factor receptor-activating mutation-positive non-small-cell lung cancer patients in Hong Kong.
    Lee VW; Schwander B; Lee VH
    Hong Kong Med J; 2014 Jun; 20(3):178-86. PubMed ID: 24281768
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Erlotinib in lung cancer.
    Pao W; Ladanyi M; Miller VA;
    N Engl J Med; 2005 Oct; 353(16):1739-41; author reply 1739-41. PubMed ID: 16240471
    [No Abstract]   [Full Text] [Related]  

  • 4. Erlotinib in lung cancer.
    Takano T; Ohe Y
    N Engl J Med; 2005 Oct; 353(16):1739-41; author reply 1739-41. PubMed ID: 16240472
    [No Abstract]   [Full Text] [Related]  

  • 5. Targeting EGFR in non-small-cell lung cancer.
    Doroshow JH
    N Engl J Med; 2005 Jul; 353(2):200-2. PubMed ID: 16014890
    [No Abstract]   [Full Text] [Related]  

  • 6. Optimising therapy for EGFR-addicted NSCLC: just the start.
    Govindan R; Subramanian J
    Lancet Oncol; 2012 Mar; 13(3):216-7. PubMed ID: 22285167
    [No Abstract]   [Full Text] [Related]  

  • 7. Assessing EGFR mutations.
    Marchetti A; Felicioni L; Buttitta F
    N Engl J Med; 2006 Feb; 354(5):526-8; author reply 526-8. PubMed ID: 16452569
    [No Abstract]   [Full Text] [Related]  

  • 8. [Erlotinib in non-small cell lung cancer].
    Takeda M; Okamoto I
    Gan To Kagaku Ryoho; 2011 Jun; 38(6):896-900. PubMed ID: 21677478
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Erlotinib or gefitinib for non-small-cell lung cancer.
    Kaye FJ; Jantz MA; Dallas J
    N Engl J Med; 2011 Jun; 364(24):2367; author reply 2368. PubMed ID: 21675909
    [No Abstract]   [Full Text] [Related]  

  • 10. [Mutations in the epidermal growth factor receptor and targeted therapy of non-small-cell lung cancer].
    Lai RS; Xie L; Shen LS; He YM; Zhu CL
    Zhonghua Bing Li Xue Za Zhi; 2005 Nov; 34(11):745-6. PubMed ID: 16536324
    [No Abstract]   [Full Text] [Related]  

  • 11. Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.
    Takeda M; Okamoto I; Tsurutani J; Oiso N; Kawada A; Nakagawa K
    Jpn J Clin Oncol; 2012 Jun; 42(6):528-33. PubMed ID: 22457323
    [TBL] [Abstract][Full Text] [Related]  

  • 12. First case of A859T epidermal growth factor receptor mutation responding to erlotinib.
    Le Maignan L; Mirebeau-Prunier D; Vervueren L; Jeanfaivre T; Urban T; Hureaux J
    J Thorac Oncol; 2011 Mar; 6(3):639-40. PubMed ID: 21317745
    [No Abstract]   [Full Text] [Related]  

  • 13. Two generations of light/never-smokers with advanced adenocarcinoma of the lung with durable responses to erlotinib.
    Pennell NA; Yin L; Keshtgarpour M; Ma PC
    J Thorac Oncol; 2012 Jul; 7(7):1200-1. PubMed ID: 22706608
    [No Abstract]   [Full Text] [Related]  

  • 14. Erlotinib in lung cancer.
    Nabhan C; Bitran JD
    N Engl J Med; 2005 Oct; 353(16):1739-41; author reply 1739-41. PubMed ID: 16236747
    [No Abstract]   [Full Text] [Related]  

  • 15. Lung cancer response to gefitinib, then erlotinib, then gefitinib again.
    Wong AS; Seto KY; Chin TM; Soo RA
    J Thorac Oncol; 2008 Sep; 3(9):1077-8. PubMed ID: 18758318
    [No Abstract]   [Full Text] [Related]  

  • 16. Cost-effectiveness of epidermal growth factor receptor-targeting tyrosine kinase inhibitors.
    Leung JS
    Hong Kong Med J; 2014 Oct; 20(5):465. PubMed ID: 25307078
    [No Abstract]   [Full Text] [Related]  

  • 17. Practical solutions to epidermal growth factor receptor tyrosine kinase inhibitor dose modifications in resource-constrained settings: Thinking outside the (packaging) box.
    Singh N; Prasad KT
    Indian J Cancer; 2017; 54(1):186-187. PubMed ID: 29199687
    [No Abstract]   [Full Text] [Related]  

  • 18. EGFR inhibitors for wild-type EGFR NSCLC: to use or not to use?
    Jassem J; Dziadziuszko R
    Lancet Oncol; 2013 Sep; 14(10):916-7. PubMed ID: 23883923
    [No Abstract]   [Full Text] [Related]  

  • 19. Flipped script for gefitinib: A reapproved tyrosine kinase inhibitor for first-line treatment of epidermal growth factor receptor mutation positive metastatic nonsmall cell lung cancer.
    Bogdanowicz BS; Hoch MA; Hartranft ME
    J Oncol Pharm Pract; 2017 Apr; 23(3):203-214. PubMed ID: 26911477
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mind your elders: therapeutic implications of epidermal growth factor receptor inhibition in older patients with advanced non-small-cell lung cancer.
    Langer CJ
    J Clin Oncol; 2007 Mar; 25(7):751-3. PubMed ID: 17228017
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.